vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and FORRESTER RESEARCH, INC. (FORR). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $101.1M, roughly 1.4× FORRESTER RESEARCH, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -33.5%, a 69.0% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -6.5%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-4.3M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 0.5%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Forrester Research, Inc. is a research and advisory firm working in research, consulting and events. Forrester’s clients include large global business, technology and consumer enterprises. The firm is headquartered in Cambridge, MA.
ADMA vs FORR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $101.1M |
| Net Profit | $49.4M | $-33.9M |
| Gross Margin | 63.8% | 56.7% |
| Operating Margin | 45.1% | -36.6% |
| Net Margin | 35.5% | -33.5% |
| Revenue YoY | 18.4% | -6.5% |
| Net Profit YoY | -55.9% | -7941.4% |
| EPS (diluted) | $0.20 | $-1.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $101.1M | ||
| Q3 25 | $134.2M | $94.3M | ||
| Q2 25 | $122.0M | $111.7M | ||
| Q1 25 | $114.8M | $89.9M | ||
| Q4 24 | $117.5M | $108.0M | ||
| Q3 24 | $119.8M | $102.5M | ||
| Q2 24 | $107.2M | $121.8M | ||
| Q1 24 | $81.9M | $100.1M |
| Q4 25 | $49.4M | $-33.9M | ||
| Q3 25 | $36.4M | $-2.1M | ||
| Q2 25 | $34.2M | $3.9M | ||
| Q1 25 | $26.9M | $-87.3M | ||
| Q4 24 | $111.9M | $432.0K | ||
| Q3 24 | $35.9M | $-5.8M | ||
| Q2 24 | $32.1M | $6.3M | ||
| Q1 24 | $17.8M | $-6.7M |
| Q4 25 | 63.8% | 56.7% | ||
| Q3 25 | 56.3% | 60.0% | ||
| Q2 25 | 55.1% | 55.5% | ||
| Q1 25 | 53.2% | 55.9% | ||
| Q4 24 | 53.9% | 58.8% | ||
| Q3 24 | 49.8% | 60.5% | ||
| Q2 24 | 53.6% | 57.3% | ||
| Q1 24 | 47.8% | 54.9% |
| Q4 25 | 45.1% | -36.6% | ||
| Q3 25 | 38.0% | 4.7% | ||
| Q2 25 | 35.1% | 6.2% | ||
| Q1 25 | 30.4% | -97.5% | ||
| Q4 24 | 32.6% | -0.5% | ||
| Q3 24 | 33.1% | -0.7% | ||
| Q2 24 | 36.6% | 9.3% | ||
| Q1 24 | 26.7% | -9.3% |
| Q4 25 | 35.5% | -33.5% | ||
| Q3 25 | 27.1% | -2.3% | ||
| Q2 25 | 28.1% | 3.5% | ||
| Q1 25 | 23.4% | -97.1% | ||
| Q4 24 | 95.2% | 0.4% | ||
| Q3 24 | 30.0% | -5.7% | ||
| Q2 24 | 29.9% | 5.2% | ||
| Q1 24 | 21.7% | -6.7% |
| Q4 25 | $0.20 | $-1.75 | ||
| Q3 25 | $0.15 | $-0.11 | ||
| Q2 25 | $0.14 | $0.20 | ||
| Q1 25 | $0.11 | $-4.62 | ||
| Q4 24 | $0.45 | $0.02 | ||
| Q3 24 | $0.15 | $-0.30 | ||
| Q2 24 | $0.13 | $0.33 | ||
| Q1 24 | $0.08 | $-0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $63.3M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $126.5M |
| Total Assets | $624.2M | $404.0M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $63.3M | ||
| Q3 25 | $61.4M | $65.1M | ||
| Q2 25 | $90.3M | $67.8M | ||
| Q1 25 | $71.6M | $75.6M | ||
| Q4 24 | $103.1M | $56.1M | ||
| Q3 24 | $86.7M | $62.8M | ||
| Q2 24 | $88.2M | $58.9M | ||
| Q1 24 | $45.3M | $61.4M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $126.5M | ||
| Q3 25 | $431.2M | $157.7M | ||
| Q2 25 | $398.3M | $159.5M | ||
| Q1 25 | $373.4M | $147.4M | ||
| Q4 24 | $349.0M | $229.5M | ||
| Q3 24 | $231.9M | $234.3M | ||
| Q2 24 | $188.3M | $237.1M | ||
| Q1 24 | $153.7M | $230.9M |
| Q4 25 | $624.2M | $404.0M | ||
| Q3 25 | $568.7M | $414.2M | ||
| Q2 25 | $558.4M | $436.0M | ||
| Q1 25 | $510.6M | $439.8M | ||
| Q4 24 | $488.7M | $503.9M | ||
| Q3 24 | $390.6M | $505.3M | ||
| Q2 24 | $376.4M | $524.2M | ||
| Q1 24 | $350.9M | $555.7M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-3.2M |
| Free Cash FlowOCF − Capex | $34.6M | $-4.3M |
| FCF MarginFCF / Revenue | 24.8% | -4.2% |
| Capex IntensityCapex / Revenue | 0.8% | 1.1% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $18.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-3.2M | ||
| Q3 25 | $13.3M | $1.2M | ||
| Q2 25 | $21.1M | $-3.6M | ||
| Q1 25 | $-19.7M | $26.7M | ||
| Q4 24 | $50.2M | $-1.8M | ||
| Q3 24 | $25.0M | $264.0K | ||
| Q2 24 | $45.6M | $-2.9M | ||
| Q1 24 | $-2.2M | $611.0K |
| Q4 25 | $34.6M | $-4.3M | ||
| Q3 25 | $-1.1M | $524.0K | ||
| Q2 25 | $18.7M | $-4.2M | ||
| Q1 25 | $-24.4M | $26.1M | ||
| Q4 24 | $47.5M | $-2.5M | ||
| Q3 24 | $24.0M | $-223.0K | ||
| Q2 24 | $43.6M | $-3.7M | ||
| Q1 24 | $-4.6M | $-815.0K |
| Q4 25 | 24.8% | -4.2% | ||
| Q3 25 | -0.8% | 0.6% | ||
| Q2 25 | 15.3% | -3.8% | ||
| Q1 25 | -21.2% | 29.0% | ||
| Q4 24 | 40.4% | -2.3% | ||
| Q3 24 | 20.0% | -0.2% | ||
| Q2 24 | 40.7% | -3.1% | ||
| Q1 24 | -5.6% | -0.8% |
| Q4 25 | 0.8% | 1.1% | ||
| Q3 25 | 10.7% | 0.7% | ||
| Q2 25 | 2.0% | 0.5% | ||
| Q1 25 | 4.1% | 0.7% | ||
| Q4 24 | 2.3% | 0.6% | ||
| Q3 24 | 0.9% | 0.5% | ||
| Q2 24 | 1.9% | 0.7% | ||
| Q1 24 | 2.9% | 1.4% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | -0.93× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | -4.24× | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | -0.46× | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
